EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS) announced positive results from a recently completed site application study demonstrating that ANTUROL®, it’s oxybutynin ATD™ transdermal gel, was absorbed on a bioequivalent basis after a single-dose was applied to three different skin site locations.
